Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-27T09:58:06.164Z Has data issue: false hasContentIssue false

Chapter 13 - Severe thrombophilias

from Section 2 - Special considerations in pediatric patients

Published online by Cambridge University Press:  18 December 2014

Cameron C. Trenor III
Affiliation:
Harvard Medical School
Marilyn J. Manco-Johnson
Affiliation:
University of Colorado
Neil A. Goldenberg
Affiliation:
The Johns Hopkins University School of Medicine
Marilyn J. Manco-Johnson
Affiliation:
Hemophilia and Thrombosis Center, University of Colorado, Denver
Get access

Summary

Introduction

Thrombophilia denotes a constitutional predisposition to thrombosis; thrombophilic traits may be genetic or acquired. It has not been standard practice to grade thrombophilia by severity, but such a grading could have practical clinical import. Grading of thrombophilia may be performed in a number of ways. The severity of thrombophilia may be regarded as the magnitude of the risk for first (incident) thrombosis, risk for thrombus recurrence or risk for poor thrombotic outcomes such as death or post-thrombotic syndrome. Severity of thrombophilia may also denote the clinical severity of the thrombotic episode, such as thrombotic storm or purpura fulminans. “Thrombophilia,” if extended to the larger context of prothrombotic risk beyond blood-based predisposing factors, can also be anatomic, such as external venous compression (e.g., Paget–Schroetter, May–Thurner); however, we will focus in this chapter on hematologic thrombophilia. This includes enhanced procoagulants, diminished anticoagulants and diminished fibrinolysis as mechanisms leading to increased thrombosis.

Genetic thrombophilic traits judged to be more potent often present at an earlier age or manifest recurrence soon after discontinuation of anticoagulation for a previous event. Patients with severe thrombophilia may spontaneously initiate a thrombotic event, while most experience a provoking trigger, tipping the balance in favor of thrombosis. However, the severe thrombophilias may require only a slight trigger (i.e., a mild upper respiratory infection), which may result in sustained activation of coagulation and progressive thrombosis even despite conventional antithrombotic drugs at typical target anticoagulant activity and duration. In this chapter we attempt to describe the subset of pediatric thrombotic syndromes that are clinically very severe and require a high index of suspicion, prompt diagnosis and immediate institution of appropriate therapy for a favorable outcome.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Goldenberg, NA, Manco-Johnson, MJ. Protein C deficiency. Haemophilia 2008;14:1214–21.CrossRefGoogle ScholarPubMed
Douglas, AGL, Rafferty, H, Hodgkins, P, Nagra, A, Foulds, NC, Morgan, M, Temple, IK. Persistent fetal vasculature and severe protein C deficiency. Mol Syndromol 2010;1:82–6.CrossRefGoogle ScholarPubMed
Manco-Johnson, MJ, Knoebl, P, Shapiro, AD, Finnerty, M, Leman, Y, Gelmont, D. Registry of patients treated with protein C concentrate (human) in the United States and Europe: Interim results. Annual Meeting of the American Society of Hematology, 12/7/2013, Abst #1146.Google Scholar
Dreyfus, M, Masterson, M, David, M, Rivard, GE, Müller, FM, Kreuz, W, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995;21:371–81.CrossRefGoogle ScholarPubMed
Zimbelman, J, Lefkowitz, J, Schaeffer, C, Hays, T, Manco-Johnson, M, Mannhalter, C, Nuss, R. Unusual complications of warfarin therapy: skin necrosis and priapism. J Pediatr 2000;136446–53.Google ScholarPubMed
Gruppo, RA, Leimer, P, Francis, RB, Marlar, RA, Silberstein, E. Protein C deficiency resulting from possible double heterozygosity and its response to danazol. Blood 1988;71:370–4.Google ScholarPubMed
Tait, RC, Walker, ID, Reitsma, PH, Islam, SI, McCall, F, Poort, SR, Conkie, JA, Bertina, RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995;73:87–93.Google ScholarPubMed
Miletich, J, Sherman, L, Broze, GAbsence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991–6.CrossRefGoogle ScholarPubMed
Reitsma, PH. Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res 1996;24:157–9.CrossRefGoogle ScholarPubMed
Junge, U, Wienke, , Schüler, A. Acute Budd-Chiari syndrome, portal and splenic vein thrombosis in a patient with ulcerative colitis associated with antiphospholipid antibodies and protein C deficiency. Gastroenterol 2001;39:845–52.Google Scholar
Devilat, M, Toso, M, Morales, M. Childhood stroke associated with protein C or S deficiency and primary antiphospholipid syndrome. Pediatr Neurol 1993;9:67–70.CrossRefGoogle ScholarPubMed
Gruppo, R, DeGrauw, A, Fogelson, H, Glauser, T, Balasa, V, Gartside, P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr 2000;137:14–18.CrossRefGoogle ScholarPubMed
Farah, RA, Jalkh, KS, Farhat, HZ, Sayad, PE, Kadri, AM. Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal and intestinal infarction. Blood Coagul Fibrinolysis 2011;22:140–3.CrossRefGoogle Scholar
Bernard, G, Vincent, J-L, Laterre, P-F, LaRosa, SP, Dhainaut, J-F, Lopez-Rodriquez, A, Steingrub, JS, Garger, GE, Helterbrand, JD, Ely, EW, Fisher, CJ, Efficacy and safety of recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group. New Engl J Med 2001;344:699–709.CrossRefGoogle Scholar
Nadel, S, Goldstein, B, Williams, MD, DAlton, H, Peters, M, Macias, WL, Abd-Allah, SA, Levy, H, Angle, R, Wang, D, Sundin, DP, Giroir, B. REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Lancet 2007;369:836–43.CrossRefGoogle Scholar
Manco-Johnson, MJ, Knapp-Clevenger, R. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. J Pediatr Hematol/Oncol 2004;26:25–7.CrossRefGoogle ScholarPubMed
Mahasandana, C, Suvatte, V, Marlar, RA, Manco-Johnson, MJ, Jacobson, L, Hathaway, WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990;335:61–2.CrossRefGoogle ScholarPubMed
Martinelli, I, Bucciarelli, P, Artoni, A, Fossali, EF, Passamonti, SM, Tripodi, A, Peyvandi, F. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics 2013;132:e1435.CrossRefGoogle ScholarPubMed
Mintz-Hittner, HA, Miyashiro, MJ, Knight-Nanan, DM, O’Malley, RE, Marlar, RA. Vitreoretinal findings similar to retinopathy of prematurity in infants with compound heterozygous protein S deficiency. Ophthalmology 1999;106:1525–30.CrossRefGoogle ScholarPubMed
Pung-Amritt, P, Poort, SR, Vos, HL, Bertina, RM, Mahasandana, C, Tanphaichitr, VS, Veerakul, G, Kankirawatana, S, Suvatte, V. Compound heterozygosity for one novel and one recurrent mutation in a Thai patient with severe protein S deficiency. Thromb Haemost 1999;81:189–92.Google Scholar
Köner, Ö, Tekin, S, Soybir, N, Gülcan, F, Karaoğlu, K. Cardiac operation in a patient with combined homozygous protein C and protein S deficiency. J Cardiothor Vasc Anesth 2000;14:188–90.CrossRefGoogle Scholar
Gandrille, S, Borgel, D, Ireland, H, Lane, DA, Simmonds, R, Reitsma, PH, Mannhalter, C, Pabinger, I, Saito, H, Suzuki, K, Formstone, C, Cooper, DN, Espinoza, Y, Sala, N, Bernardi, F, Aiach, M. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:1201–14.Google ScholarPubMed
Manco-Johnson, MJ, Nuss, R, Key, N, Moertel, C, Jacobson, L, Meech, S, Weinberg, A, Lefkowitz, J. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996;128:319–23.CrossRefGoogle ScholarPubMed
Josephson, C, Nuss, R, Jacobson, L, Hacker, MR, Murphy, J, Weinberg, A, Manco-Johnson, MJ. The varicella–autoantibody syndrome. Pediatr Res 2001;50:345–52.CrossRefGoogle ScholarPubMed
Orlando, C, Lissens, W, Hasaerts, D, Jochmans, K. Identification of two de novo mutations responsible for type I antithrombin deficiency. Thromb Haemost 2012;107:187–9.CrossRefGoogle ScholarPubMed
Kumar, R, Moharir, M, Yau, I, Williams, S. A novel mutation in the Serpin C1 gene presenting as unprovoked cerebral sinus venous thrombosis in a kindred. Pediatr Blood Cancer 2013;60:133–6.CrossRefGoogle Scholar
Chowdhury, V, Lane, DA, Mille, B, Auberger, K, Gandenberger-Bachem, S, Pabinger, I, Olds, RJ, Thein, SL. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994;72:198–202.Google ScholarPubMed
Olivieri, M, Bidlingmaier, C, Schetzeck, S, Borggräfe, I, Geisen, C, Kurnik, K. Arterial thrombosis in homozygous antithrombin deficiency. Hamostaseologie 2012;32 Suppl 1:S79–82.Google ScholarPubMed
Pascaul, C, Muñoz, C, Huerta, AR, Rus, GP, Ortega, V, Corral, J, Diez-Martin, JL. A new case of successful outcome of pregnancy in a carrier of homozygous type II (L99F) antithrombin deficiency. Blood Coagul Fibrinolysis 2014;25:74–6.CrossRefGoogle Scholar
Patnaik, MM, Moll, S. Inherited antithrombin deficiency: a review. Haemophilia 2008;14:1229–39.CrossRefGoogle ScholarPubMed
Lane, DA, Bayston, R, Olds, RJ, Fitches, AC, Cooper, DN, Millar, DS, Jochmans, K, Perry, DJ, Okajima, K, Thein, SL, Emmerich, J. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:1979–211.Google ScholarPubMed
Bucur, SZ, Levy, JH, Despotis, GJ, Spiess, BD, Hillyer, CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38:481–98.CrossRefGoogle ScholarPubMed
Sheridan-Pereira, M, Porreco, RP, Hays, T, Burke, MS. Neonatal aortic thrombosis associated with the lupus anticoagulant. Obstet Gynecol 1988;71:1016–18.Google ScholarPubMed
Menache, D, O’Malley, JP, Schorr, JB, Wagner, B, Williams, C, and the Cooperative Study Group: Alving, BM, Ballard, JO, Goodnight, SH, Hathaway, WE, Hultin, MB, Kitchens, CS, Lessner, HE, Makary, AZ, Manco-Johnson, M, McGhee, WG, Penner, JA, Sanders, JE. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990;75:33–9.Google ScholarPubMed
Wong, TE, Huang, Y-S, Weiser, J, Brogan, TV, Shah, SS, Witmer, CM. Antithrombin concentrate use in children: a multicenter cohort study. J Pediatr 2013;163:1329–34.CrossRefGoogle ScholarPubMed
Bornikova, L, Peyvandi, F, Allen, G, Bernstein, J, Manco-Johnson, MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011;9:1687–704.CrossRefGoogle ScholarPubMed
Mosesson, MW. Antithrombin, I. Inhibition of thrombin regulation in plasma by fibrin formation. Thromb Haemost 2003;89:9–12.Google Scholar
Ni, H, Denis, CV, Subbarao, S, Degen, JL, Sato, TN, Hynes, RO, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106:385–92.CrossRefGoogle ScholarPubMed
Dupuy, E, Soria, C, Molho, P, Zini, JM, Rosenstingl, S, Laurian, C, Bruneval, P, Tobelem, G. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001;102:211–19.CrossRefGoogle Scholar
Niwa, K, Mimuro, J, Miyata, M, Sugo, T, Ohmori, T, Madoiwa, S, Tei, C, Sakata, Y. Dysfibrinogenemia Kagoshima with the amino acid substitution ɤThr-314 to Ile: Analysis of molecular abnormalities and thrombophilic nature of this abnormal molecule. Thromb Res 2008;121:773–80.CrossRefGoogle Scholar
Niwa, K, Yaginuma, A, Nakanishi, M, Wada, Y, Sugo, T, Asakura, S, Watanabe, N, Matsuda, M. Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an A alpha Glu-11 to Gly substitution. Blood 1993;82:3658–63.Google ScholarPubMed
Ramanathan, R, Gram, J, Feddersen, S, Nybo, M, Larsen, A, Sidelmann, JJ. Dusart syndrome in a Scandinavian family characterized by arterial and venous thrombosis at young age. Scand J Clin Lab Invest 2013;73:585–90.CrossRefGoogle Scholar
Huang, ZF, Higuchi, D, Lasky, N, Broze, GJTissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997;90:944–51.Google ScholarPubMed
Kentsis, A, Bradwin, G, Miller, DT, Trenor, CCVenous thrombosis associated with gene deletion of tissue factor pathway inhibitor. Am J Hematol 2009;84:775–6.CrossRefGoogle ScholarPubMed
Mudd, SH, Skovby, F, Levy, HL, Pettigrew, KD, Wilcken, B, Pyeritz, RE, Andria, G, Boers, GH, Bromberg, IL, Cerone, R, Fowler, B, Gröbe, H, Schmidt, H, Schweitzer, L. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1–31.Google ScholarPubMed
Undas, A, Brozek, J, Szczeklik, A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005;94:907–15.Google ScholarPubMed
Linssen, M, Mohamed, M, Wevers, RA, Lefeber, DJ, Morava, E. Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab 2013;109:107–11.CrossRefGoogle ScholarPubMed
Tsai, H-M. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013;126:200–9.CrossRefGoogle ScholarPubMed
Zipfel, PF, Wolf, G, John, U, Kentouche, K, Skerka, C. Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytopenic purpura?Pediatr Nephrol 2011;26:1947–56.CrossRefGoogle Scholar
Lowe, EJ, Werner, EJ. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost 2005;31:717–29.CrossRefGoogle ScholarPubMed
Gruppo, RA, Rother, RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. NEJM 2009;360:544–6.CrossRefGoogle ScholarPubMed
Carreras, L, Romero, R, Requesens, C, Oliver, AJ, Carrera, M, Clavo, M, Alsina, J. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA 1981;245:602–4.CrossRefGoogle ScholarPubMed
Skerka, C, Chen, Q, Fremeaux-Bacchi, V, Roumenina, LT. Complement factor H proteins (CFHRs). Mol Immunol 2013;56:170–80CrossRefGoogle Scholar
Zheng, XL, Sadler, JE. Pathogenesis of thrombotic microangiopathies. Ann Rev Pathol Mech Dis. 2008;3:249–77.CrossRefGoogle ScholarPubMed
Levy, GG, Nichols, WC, Lian, EC, Foroud, T, McClintick, JN, McGee, BM, Yang, AY, Siemieniak, DR, Stark, KR, Gruppo, R, Sarode, R, Shurin, SB, Chandrasekaran, V, Stabler, SP, Sabio, H, Bouhassira, EE, Upshaw, JD, Ginsburg, D, Tsai, HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenia purpura. Nature 2001;413:488–94.CrossRefGoogle Scholar
Franchini, M, Zaffanello, M, Veneri, O. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res 2006;118:177–84.CrossRefGoogle ScholarPubMed
Shibagaki, Y, Matsumoto, M, Kokame, K, Ohba, S, Miyata, T, Fujimura, Y, Fujita, T. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS gene in an adult patient with Upshaw-Shulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 2006;21:1289–92.CrossRefGoogle Scholar
Barbot, J, Costa, E, Guerra, M, Barreirinho, MS, Isvarlal, P, Robles, R, Gerritesen, HE, Lämmle, B, Furlan, M. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001;113:649–51.CrossRefGoogle Scholar
Uvaraj, P, Rathisharmila, R, Ilamaran, V. Protein C and protein S deficiency presenting as Budd-Chiari syndrome. Blood Coag Fibrinolysis 2013;24:652–4.CrossRefGoogle ScholarPubMed
Köller, H, Stoll, G, Sitzer, M, Burk, M, Schöttler, B, Freund, HJ. Deficiency of both protein C and protein S in a family with ischemic strokes in young adults. Neurology 1994;44:1238–40.CrossRefGoogle Scholar
Laczika, K, Lang, IM, Quehenberger, P, Mannhalter, C, Muhm, M, Klepetko, W, Kyrle, PA. Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. Chest 2002;121:286–9.CrossRefGoogle ScholarPubMed
Kosch, A, Junker, R, Wermes, C, Nowak-Göttl, U. Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a). Thromb Res 2002;105(1):49–53.CrossRefGoogle Scholar
Inbal, A, Kenet, G, Zivelin, A, Yermiyahu, T, Bronstein, T, Sheinfeld, T, Tamari, H, Gitel, S, Eshel, G, Duchemin, J, Aiach, M, Seligsohn, U. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 1997;77(6):1086–9.Google ScholarPubMed
Salomon, O, Steinberg, DM, Zivelin, A,Gitel, S, Dardik, R, Rosenberg, N, Berliner, S, Inbal, A, Many, A, Lubetsky, A, Varon, D, Martinowitz, U, Seligsohn, U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511–18.CrossRefGoogle ScholarPubMed
Asherson, RA. The primary, secondary, catastrophic and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 2008;34:227–35.CrossRefGoogle Scholar
Cervera, R, Espinosa, G. Update on the Catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012;38:333–8.Google ScholarPubMed
Cervara, R and CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus 2010;19:412–18.CrossRefGoogle Scholar
Erkan, D, Asherson, RA, Espinosa, G, Cervera, R, Font, J, Piette, J-C, Lockshin, MD. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003;62:530–3.CrossRefGoogle ScholarPubMed
Camacho-Lovillo, S, Bernabeu-Wittel, J, Iglesias-Jimenez, E, Falcón-Neyra, D, Neth, O. Pediatr Dermatol 2013;30:e63–64.CrossRef
Olivier, C, Blondiaux, E, Blanc, T, Borg, J-Y, Dacher, J-N. Catastrophic antiphospholipid syndrome and pulmonary embolism in a 3-year-old child. Pediatr Radiol 2006;36:870–73.CrossRefGoogle Scholar
Ortel, TL, Kitchens, CS, Erkan, D, Brandão, LR, Hahn, S, James, AH, Kulkarni, R, Manco-Johnson, MJ, Pericak-Vance, MJ, Vance, J. Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol 2012;5:653–9.CrossRefGoogle ScholarPubMed
Manco-Johnson, MJ, Wang, M, Goldenberg, NA. Treatment, survival and thromboembolic outcomes of thrombotic storm in children. J Pediatr 2012;161:682–8.e1.CrossRefGoogle ScholarPubMed
Karpman, D, Sartz, L, Johnson, S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:575–85.CrossRefGoogle ScholarPubMed
Amirlak, I, Amirlak, B. Haemolytic uraemic syndrome: an overview. Nephrology 2006;11:213–18.CrossRefGoogle ScholarPubMed
Bouw, MC, Dors, N, van Ommen, H, Ramakers-van Woerden NL. Thrombotic thrombocytopenia in childhood. Pediatr Blood Cancer 2009;53:537–42.CrossRefGoogle ScholarPubMed
Moake, J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Prac Res Clin Haematol 2009;22:567–76.CrossRefGoogle ScholarPubMed
Hill, A, Kelly, RJ, Hillmen, P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013;121:4985–96CrossRefGoogle ScholarPubMed
Borowitz, MJ, Craig, FE, Digiuseppe, JA, Illingworth, AJ, Rosse, W, Sutherland, DR, Wittwer, CT, Richards SJ; on behalf of the Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom B Clin Cyt 2010;78B:211–30.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×